GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zafgen Inc (NAS:ZFGN) » Definitions » Peter Lynch Fair Value

Zafgen (Zafgen) Peter Lynch Fair Value : $-200.68 (As of May. 06, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Zafgen Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Zafgen's PEG is 1. Zafgen's 5-Year TTM EBITDA Growth Rate is 17.42. Zafgen's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2020 was $-11.52. Therefore, the Peter Lynch Fair Value for today is $-200.68.

As of today (2024-05-06), Zafgen's share price is $0.99. Zafgen's Peter Lynch fair value is $-200.68. Therefore, Zafgen's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for Zafgen's Peter Lynch Fair Value or its related term are showing as below:



ZFGN's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Biotechnology industry.
Industry Median: 1.62
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Zafgen Peter Lynch Fair Value Historical Data

The historical data trend for Zafgen's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zafgen Peter Lynch Fair Value Chart

Zafgen Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only - - - - -

Zafgen Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zafgen's Peter Lynch Fair Value

For the Biotechnology subindustry, Zafgen's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zafgen's Price-to-Peter-Lynch-Fair-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zafgen's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Zafgen's Price-to-Peter-Lynch-Fair-Value falls into.



Zafgen Peter Lynch Fair Value Calculation

Zafgen's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 17.42 *-11.52
=-200.68

Zafgen's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.52.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Zafgen  (NAS:ZFGN) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 17.42 instead of 15 in this case.

Zafgen's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.99/-200.68
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zafgen Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Zafgen's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Zafgen (Zafgen) Business Description

Traded in Other Exchanges
N/A
Address
3 Center Plaza, Suite 610, Boston, MA, USA, 02108
Zafgen Inc is a US-based biopharmaceutical company. It focuses on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. The lead product candidate of the company is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection. The company operates in the business of developing novel therapeutics. The company primarily carries its business operations in the United States.

Zafgen (Zafgen) Headlines

From GuruFocus

Zafgen Announces Regulatory Update on ZGN-1061

By Marketwired Marketwired 05-30-2019

Zafgen Reports First Quarter 2019 Operating and Financial Results

By Marketwired Marketwired 05-10-2019

Zafgen to Present at the 31st Annual ROTH Conference

By Marketwired Marketwired 03-14-2019

Zafgen to Announce First Quarter 2019 Financial Results

By Marketwired Marketwired 05-03-2019

Zafgen: Bargain or Busted?

By John Engle John Engle 11-27-2018

Zafgen to Present at the Wedbush PacGrow Healthcare Conference

By Marketwired Marketwired 08-09-2018